Contagious cancer: Lessons from the devil and the dog

BioEssays

Volumn 34, Issue 4, 2012, Pages 285-292

  Belov, Katherine ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Canine transmissible venereal tumour; Contagious cancer; MHC; Tasmanian devil facial tumour disease

Indexed keywords

GAMMA INTERFERON; HLA G ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR;

ANIMAL VENEREAL TUMOR; ANTIGEN PRESENTATION; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNOLOGY; CANINE TRANSMISSIBLE VENEREAL TUMOR; CARNIVORE DISEASE; CD8+ T LYMPHOCYTE; COPY NUMBER VARIATION; CYTOTOXIC T LYMPHOCYTE; DEVIL FACIAL TUMOR DISEASE; DISEASE TRANSMISSION; DOG DISEASE; FACE TUMOR; GENETIC REGULATION; GENETIC VARIABILITY; HUMAN; IMMUNE EVASION; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MARSUPIAL; MIXED LYMPHOCYTE REACTION; NONHUMAN; PREDICTION; REVIEW; TASMANIAN DEVEIL;

ANIMALS; DOGS; FACIAL NEOPLASMS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MARSUPIALIA; NEOPLASMS; TASMANIA; VENEREAL TUMORS, VETERINARY;

CANIS FAMILIARIS; SARCOPHILUS HARRISII;

EID: 84858285265     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201100161     Document Type: Review

References (102)

1. Heng HH, Stevens JB, Bremer SW, Liu G, et al. 2011. Evolutionary mechanisms and diversity in cancer. Adv Cancer Res 112: 217-53.
2. Pawelec G. 2004. Immunotherapy and immunoselection - tumour escape as the final hurdle. FEBS Lett 567: 63-6.
3. McCallum H, Jones M. 2006. To lose both would look like carelessness: Tasmanian devil facial tumour disease. PLoS Biol 4: e 342.
4. Belov K. 2011. The role of the major histocompatibility complex in the spread of contagious cancers. Mamm Genome 22: 83-90.
5. Trowsdale J. The MHC, disease and selection. Immunol Lett 137: 1-8.
6. Piertney SB, Oliver MK. 2006. The evolutionary ecology of the major histocompatibility complex. Heredity 96: 7-21.
7. Yuhki N, O'Brien SJ. 1990. DNA variation of the mammalian major histocompatibility complex reflects genomic diversity and population history. Proc Natl Acad Sci USA 87: 836-40.
8. Radwan J, Biedrzycka A, Babik W. 2010. Does reduced MHC diversity decrease viability of vertebrate populations? Biol Conserv 143: 537-44.
9. Doherty PC, Zinkernagel RM. 1975. A biological role for the major histocompatibility antigens. Lancet 1: 1406-9.
10. Kelley J, Walter L, Trowsdale J. 2005. Comparative genomics of major histocompatibility complexes. Immunogenetics 56: 683-95.
11. Ujvari B, Belov K. 2011. Major histocompatibility complex (MHC) markers in conservation biology. Int J Mol Sci 12: 5168-86.
12. Siddle HV, Deakin JE, Coggill P, Whilming L, et al. 2011. The tammar wallaby major histocompatibility complex shows evidence of past genomic instability. BMC Genomics 12: 421.
13. Siddle HV, Deakin JE, Coggill P, Hart E, et al. 2009. MHC-linked and un-linked class I genes in the wallaby. BMC Genomics 10: 310.
14. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, et al. 2004. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53: 904-10.
15. Bubenik J. 2004. MHC class I down-regulation: Tumour escape from immune surveillance? (review). Int J Oncol 25: 487-91.
16. Cabrera T, Maleno I, Lopez-Nevot MA, Redondo M, et al. 2003. High frequency of HLA-B44 allelic losses in human solid tumors. Hum Immunol 64: 941-50.
17. Cabrera T, Pedrajas G, Cozar JM, Garrido A, et al. 2003. HLA class I expression in bladder carcinomas. Tissue Antigens 62: 324-7.
18. Ferrone S, Marincola FM. 1995. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16: 487-94.
19. Garcia-Lora A, Algarra I, Garrido F. 2003. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195: 346-55.
20. Ugurel S, Reinhold U, Tilgen W. 2002. HLA-G in melanoma: A new strategy to escape from immunosurveillance? Onkologie 25: 129-34.
21. Moffett A, Loke C. 2006. Immunology of placentation in eutherian mammals. Nat Rev Immunol 6: 584-94.
22. Kennedy LJ. 2007. 14th International HLA and Immunogenetics Workshop: report on joint study on canine DLA diversity. Tissue Antigens 69: 269-71.
23. Kennedy LJ, Angles JM, Barnes A, Carmichael LE, et al. 2007. DLA-DRB1, DQA1, and DQB1 alleles and haplotypes in North American gray wolves. J Hered 98: 491-9.
24. Siddle HV, Marzec J, Cheng Y, Jones M, et al. 2010. MHC gene copy number variation in Tasmanian devils: implications for the spread of a contagious cancer. Proc Biol Sci 277: 2001-6.
25. Cheng Y, Stuart A, Morris K, Taylor R, et al. 2011. BAC-based sequence of Tasmanian devil MHC. BMC Genomics, in press.
26. Siddle HV, Kreiss A, Eldridge MD, Noonan E, et al. 2007. Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proc Natl Acad Sci USA 104: 16221-6.
27. Doherty PC, Zinkernagel RM. 1975. H-2 compatibility is required for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. J Exp Med 141: 502-7.
28. Bradley BA. 1991. The role of HLA matching in transplantation. Immunol Lett 29: 55-9.
29. Warrens AN, Lombardi G, Lechler RI. 1994. Presentation and recognition of major and minor histocompatibility antigens. Transpl Immunol 2: 103-7.
30. Buss LW. 1982. Somatic cell parasitism and the evolution of somatic tissue compatibility. Proc Natl Acad Sci USA 79: 5337-41.
31. McKitrick TR, De Tomaso AW. 2010. Molecular mechanisms of allorecognition in a basal chordate. Semin Immunol 22: 34-8.
32. De Tomaso AW. 2009. Sea squirts and immune tolerance. Dis Model Mech 2: 440-5.
33. Lakkis FG, Dellaporta SL, Buss LW. 2008. Allorecognition and chimerism in an invertebrate model organism. Organogenesis 4: 236-40.
34. Nicotra ML, Powell AE, Rosengarten RD, Moreno M, et al. 2009. A hypervariable invertebrate allodeterminant. Curr Biol 19: 583-9.
35. Rosa SF, Powell AE, Rosengarten RD, Nicotra ML, et al. 2010. Hydractinia allodeterminant alr1 resides in an immunoglobulin superfamily-like gene complex. Curr Biol 20: 1122-7.
36. Campoli M, Ferrone S. 2008. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27: 5869-85.
37. Campoli M, Ferrone S. 2011. HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol 33: 321-34.
38. Johnson C. 2006. Australia 's Mammal Extinctions: a 50 000 year History. Melbourne: Cambridge University Press.
39. Bradshaw CJA, Brook BW. 2005. Disease and the devil: density-dependent epidemiological processes explain historical population fluctuations in the Tasmania devil. Ecography 28: 191-200.
40. Hawkins CE, Baars C, Hesterman H, Hocking GJ, et al. 2006. Emerging disease and population decline of an island endemic, the Tasmanian devil Sarcophilus harrisii. Biol Conserv 131: 307-24.
41. Jones ME, Paetkau D, Gefen E, Moritz C. 2004. Genetic diversity and population structure of Tasmanian devils, the largest marsupial carnivore. Mol Ecol 13: 2197-209.
42. Miller W, Hayes VM, Ratan A, Petersen DC, et al. 2011. Genetic diversity and population structure of the endangered marsupial Sarcophilus harrisii (Tasmanian devil). Proc Natl Acad Sci USA 108: 12348-53.
43. Loh R, Bergfeld J, Hayes D, O'Hara A, et al. 2006. The pathology of devil facial tumor disease (DFTD) in Tasmanian devils (Sarcophilus harrisii). Vet Pathol 43: 890-5.
44. Jones ME, Cockburn A, Hamede R, Hawkins C, et al. 2008. Life-history change in disease-ravaged Tasmanian devil populations. Proc Natl Acad Sci USA 105: 10023-7.
45. McCallum H, Tompkins DM, Jones ME, Lachish S, et al. 2007. Distribution and impacts of Tasmanian devil facial tumour disease. EcoHealth 4: 318-25.
46. Obendorf D, McGlashan ND. 2008. Research priorities in the Tasmanian devil facial tumour debate. Eur J Oncol 13: 229-38.
47. Pearse AM, Swift K. 2006. Allograft theory: transmission of devil facial-tumour disease. Nature 439: 549.
48. Murchison EP, Tovar C, Hsu A, Bender HS, et al. 2010. The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer. Science 327: 84-7.
49. Canfield PJ, Hartley WJ, Reddacliff GL. 1990. Spontaneous proliferations in Australian marsupials - a survey and review. 2. Dasyurids and bandicoots. J Comp Pathol 103: 147-58.
50. Canfield PJ, Hemsley S. 2000. The roles of histology and immunohistology in the investigation of marsupial disease and normal lymphoid tissue. Dev Comp Immunol 24: 455-71.
51. Griner L. 1979. Neoplasms in Tasmanian devils (Sarcophilus harrisii). J Nat Cancer Inst 62: 589-93.
52. Woods GM, Kreiss A, Belov K, Siddle HV, et al. 2007. The immune response and devil facial tumour disease. EcoHealth 4: 338-45.
53. Kreiss A, Wells B, Woods GM. 2009. The humoral immune response of the Tasmanian devil (Sarcophilus harrisii) against horse red blood cells. Vet Immunol Immunopathol 130: 135-7.
54. Kreiss A, Cheng Y, Kimble F, Wells B, et al. 2011. Allorecognition in the Tasmanian devil (Sarcophilus harrisii), an endangered marsupial species with limited genetic diversity. PLoS ONE 6: e22402.
55. Brown GK, Kreiss A, Lyons AB, Woods GM. 2011. Natural killer cell mediated cytotoxic responses in the Tasmanian devil. PLoS ONE 6: e24475.
56. Belov K, Sanderson CE, Deakin JE, Wong ES, et al. 2007. Characterization of the opossum immune genome provides insights into the evolution of the mammalian immune system. Genome Res 17: 982-91.
57. Wong ES, Papenfuss AT, Miller RD, Belov K. 2009. Hatching time for monotreme immunology. Aust J Zool 57: 185-98.
58. Loh R, Hayes D, Mahjoor A, O'Hara A, et al. 2006. The immunohistochemical characterization of devil facial tumor disease (DFTD) in the Tasmanian devil (Sarcophilus harrisii). Vet Pathol 43: 896-903.
59. Hamede R, Lachish S, Belov K, Woods G, et al. 2012. Reduced effect of Tasmanian devil facial tumor disease at the disease front. Conserv Biol 26: 124-34.
60. Mullally A, Ritz J. 2007. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 109: 1355-62.
61. Spencer CT, Gilchuk P, Dragovic SM, Joyce S. Minor histocompatibility antigens: presentation principles, recognition logic and the potential for a healing hand. Curr Opin Organ Transplant 15: 512-25.
62. Loveland B, Simpson E. 1986. The non-MHC transplantation antigens: neither weak nor minor. Immunology Today 7: 223-9.
63. Snell GD. 1953. The genetics of transplantation. J Natl Cancer Inst 14: 691-700. discussion 1-4.
64. LaRosa DF, Rahman AH, Turka LA. 2007. The innate immune system in allograft rejection and tolerance. J Immunol 178: 7503-9.
65. Benichou G, Yamada Y, Yun S, Lin C, et al. 2011. Immune recognition and rejection of allogeneic skin grafts. Immunotherapy 3: 757-70.
66. Murphy SP, Porrett PM, Turka LA. 2011. Innate immunity in transplant tolerance and rejection. Immunol Rev 241: 39-48.
67. Novinski MA. 1876. Zur Frage über die Impfung der krebsigen Geschwülste. Zentralbl Med Wissensch 14: 790-1.
68. Rebbeck CA, Thomas R, Breen M, Leroi AM, et al. 2009. Origins and evolution of a transmissible cancer. Evolution 63: 2340-9.
69. Das U, Das AK. 2000. Review of canine transmissible venereal sarcoma. Vet Res Commun 24: 545-56.
70. Murchison EP. 2009. Clonally transmissible cancers in dogs and Tasmanian devils. Oncogene 27: S19-30.
71. Rebbeck CA, Leroi AM, Burt A. 2011. Mitochondrial capture by a transmissible cancer. Science 331: 303.
72. Adams EW, Sapp WJ, Carter LP. 1981. Cytogenetic observations on the canine venereal tumor in long term culture. Cornell Vet 71: 336-46.
73. Liao KW, Lin ZY, Pao HN, Kam SY, et al. 2003. Identification of canine transmissible venereal tumor cells using in situ polymerase chain reaction and the stable sequence of the long interspersed nuclear element. J Vet Diagn Invest 15: 399-406.
74. Wright DH, Peel S, Cooper EH, Huges DT. 1970. Transmissible venereal sarcoma of dogs. A histochemical and chromosomal analysis of tumours in Uganda. Eur J Clin Biol Res 15: 155.
75. Murgia C, Pritchard JK, Kim SY, Fassati A, et al. 2006. Clonal origin and evolution of a transmissible cancer. Cell 126: 477-87.
76. Thomas R, Rebbeck C, Leroi AM, Burt A, et al. 2009. Extensive conservation of genomic imbalances in canine transmissible venereal tumors (CTVT) detected by microarray-based CGH analysis. Chromosome Res 17: 927-34.
77. Cohen D, Shalev A, Krup M. 1984. Lack of beta 2 microglobulin on the surface of canine transmissible venereal tumor cells. J Natl Cancer Inst 72: 395-401.
78. Yang TJ, Chandler JP, Dunne-Anway S. 1987. Growth stage dependent expression of MHC antigens on the canine transmissible venereal sarcoma. Brit J Cancer 55: 131-4.
79. Fassati A, Mitchison NA. 2010. Testing the theory of immune selection in cancers that break the rules of transplantation. Cancer Immunol Immunother 59: 643-51.
80. Hsiao YW, Liao KW, Hung SW, Chu RM. 2002. Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Vet Immunol Immunopathol 87: 19-27.
81. Hsiao YW, Liao KW, Chung TF, Liu CH, et al. 2008. Interactions of host IL-6 and IFN-gamma and cancer-derived TGF-beta1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunol Immunother 57: 1091-104.
82. Yang TJ, Jones JB. 1973. Canine transmissible venereal sarcoma: transplantation studies in neonatal and adult dogs. J Natl Cancer Inst 51: 1915-8.
83. Cohen D. 1973. The biological behaviour of the transmissible venereal tumour in immunosuppressed dogs. Eur J Cancer 9: 253-8.
84. Vonholdt BM, Pollinger JP, Lohmueller KE, Han E, et al. 2010. Genome-wide SNP and haplotype analyses reveal a rich history underlying dog domestication. Nature 464: 898-902.
85. Pearse AM, Swift K, Hodson P, Hua B, et al. 2011. Evolution in a transmissible cancer: a study of the chromosomal changes in devil facial tumour (DFT) as it spreads through the wild Tasmanian devil population. Cancer Genetics in press.
86. Frank SA. 1996. Models of parasite virulence. Q Rev Biol 71: 37-78.
87. Kreiss A, Tovar C, Obendorf DL, Dun K, et al. 2011. A murine xenograft model for a transmissible cancer in Tasmanian devils. Vet Pathol 48: 475-81.
88. Higgins DA. 1966. Observations on the canine transmissible venereal tumour as seen in the Bahamas. Vet Rec 79: 67-71.
89. Hillis DM. 2007. Asexual evolution: Can species exist without sex? Curr Biol 17: R543-4.
90. McCallum H. 2008. Tasmanian devil facial tumour disease: lessons for conservation biology. Trends Ecol Evol 23: 631-7.
91. Lachish S, Jones M, McCallum H. 2007. The impact of disease on the survival and population growth rate of the Tasmanian devil. J Anim Ecol 76: 926-36.
92. Lachish S, McCallum H, Jones M. 2009. Demography, disease and the devil: life-history changes in a disease-affected population of Tasmanian devils (Sarcophilus harrisii). J Anim Ecol 78: 427-36.
93. Lachish S, Miller KJ, Storfer A, Goldizen AW, et al. 2011. Evidence that disease-induced population decline changes genetic structure and alters dispersal patterns in the Tasmanian devil. Heredity 106: 172-82.
94. Burnet FM. 1957. Cancer - a biological approach. Brit Med J 1: 841-7.
95. Thomas L. 1959. Cellular and Humoral Aspects of the Hypersensitive States. New York: Hoeber-Harper.
96. Old JM, Deane EM. 2000. Development of the immune system and immunological protection in marsupial pouch young. Dev Comp Immunol 24: 445-54.
97. Wang J, Wong ES, Whitley JC, Li J, et al. 2011. Ancient antimicrobial peptides kill antibiotic-resistant pathogens: Australian mammals provide new options. PLoS ONE 6: e24030.
98. Renfree MB, Papenfuss AT, Deakin JE, Lindsay J, et al. 2011. Genome sequence of an Australian kangaroo, Macropus eugenii, provides insight into the evolution of mammalian reproduction and development. Genome Biol 12: R81.
99. Daly KA, Digby M, Lefevre C, Mailer S, et al. 2007. Analysis of the expression of immunoglobulins throughout lactation suggests two periods of immune transfer in the tammar wallaby (Macropus eugenii). Vet Immunol Immunopathol 120: 187-200.
100. Daly KA, Digby MR, Lefevre C, Nicholas KR, et al. 2008. Identification, characterization and expression of cathelicidin in the pouch young of tammar wallaby (Macropus eugenii). Comp Biochem Physiol B: Biochem Mol Biol 149: 524-33.
101. Pyecroft S, Pearse AM, Loh R, Swift K, et al. 2007. Towards a case definition for Devil Facial Tumour Disease: What is it? EcoHealth 4: 346-51.
102. Hamede RK, Bashford J, McCallum H, Jones M. 2009. Contact networks in a wild Tasmanian devil (Sarcophilus harrisii) population: using social network analysis to reveal seasonal variability in social behaviour and its implications for transmission of devil facial tumour disease. Ecol Lett 12: 1147-57.